 Home > Active Ingredient News > Antitumor Therapy > Over 30 Class 1 new drugs were approved in clinical trials this week, including systemic lupus erythematosus, tumors and other fields

Over 30 Class 1 new drugs were approved in clinical trials this week, including systemic lupus erythematosus, tumors and other fields

 Last Update: 2021-11-11
 Source: Internet
 Author: User

Tags

effexor mechanism action

mu receptor antagonist

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

(People’s Daily Health Client Li Xuanzhang) According to incomplete statistics from the People’s Daily Health Client, this week, the Drug Evaluation Center of the State Drug Administration announced that over 30 Class 1 new drugs have been approved for clinical trials.

Domestic pharmaceutical companies

The clinical trial application of Junshi Biologics UBP1213sc injection (project code "UBP1213sc") was approved this week, and the indication is systemic lupus erythematosus

The application for the clinical trial of SKB315 for injection developed by the subsidiary of Kelun Pharmaceutical Co.

Bencao Ruisheng’s ricolinostat clinical trial application was approved this week, and its indication is chemotherapy-induced peripheral neuropathy (CIPN)

Quanxin Biotech's QX005N injection clinical trial application was approved this week, and the indication is chronic sinusitis with nasal polyps

Gale’s application for the clinical trial of ASC22 injection was approved this week, and the indication is adult human immunodeficiency virus (HIV) infection

The clinical trial application of IMM27M injection for IMM27M injection was approved this week, and the indication is for advanced solid tumors

Foreign pharmaceutical companies

Novartis' LNP023 capsule clinical trial application was approved this week, and its indications are primary IgA nephropathy and early to mid-stage age-related macular degeneration

Johnson & Johnson's JNJ-63733657 injection clinical trial application was approved this week, and the indication is Alzheimer's disease

Sanofi's rilzabrutinib caplet clinical trial application was approved this week, and its indication is adult immune thrombocytopenia

The clinical trial application of GSK3511294 injection by GlaxoSmithKline was approved this week, and the indication is the adjuvant maintenance treatment for patients with severe eosinophilic asthma

Daiichi Sankyo's DS-1062a clinical trial application was approved this week, and the indication is breast cancer

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.